## Claudio Liguori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8543301/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Metabolic dysfunction in OSA: Is there something new under the sun?. Journal of Sleep Research, 2022, 31, e13418.	1.7	31
2	PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice. Journal of Neurology, 2022, 269, 1957-1977.	1.8	34
3	Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy?. Neurological Sciences, 2022, 43, 1993-2001.	0.9	7
4	Depressive symptoms in patients with epilepsy and clinically associated features in a single tertiary center. Neurological Sciences, 2022, 43, 1965-1974.	0.9	7
5	Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinson's Disease: A Cerebrospinal Fluid-Based Study. Journal of Parkinson's Disease, 2022, 12, 537-544.	1.5	3
6	Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinson's disease: a preliminary evidence. Neurological Sciences, 2022, 43, 5355-5362.	0.9	6
7	Nocturnal Hypoxia and Sleep Fragmentation May Drive Neurodegenerative Processes: The Compared Effects of Obstructive Sleep Apnea Syndrome and Periodic Limb Movement Disorder on Alzheimer's Disease Biomarkers. Journal of Alzheimer's Disease, 2022, 88, 127-139.	1.2	8
8	18F-FDG PET, cognitiveÂfunctioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment. Journal of Neurology, 2022, 269, 5356-5367.	1.8	13
9	Not just a Snapshot: An Italian Longitudinal Evaluation of Stability of Gut Microbiota Findings in Parkinson's Disease. Brain Sciences, 2022, 12, 739.	1.1	6
10	Cognitive functioning, cerebrospinal fluid Alzheimer's disease biomarkers and cerebral glucose metabolism in lateâ€onset epilepsy of unknown aetiology: A prospective study. European Journal of Neuroscience, 2022, 56, 5384-5396.	1.2	9
11	Perampanel Increases Cortical EEG Fast Activity in Child and Adult Patients Affected by Epilepsy: A Quantitative EEG Study. Clinical EEG and Neuroscience, 2021, 52, 360-370.	0.9	11
12	Sleepâ^`wake cycle dysregulation in idiopathic REM sleep behaviour disorder. Journal of Sleep Research, 2021, 30, e13234.	1.7	7
13	Depressive and anxiety symptoms in patients with SARS-CoV2 infection. Journal of Affective Disorders, 2021, 278, 339-340.	2.0	11
14	Sleep-disordered breathing and the risk of Alzheimer's disease. Sleep Medicine Reviews, 2021, 55, 101375.	3.8	79
15	Dysregulation of the orexin/hypocretin system is not limited to narcolepsy but has farâ€reaching implications for neurological disorders. European Journal of Neuroscience, 2021, 53, 1136-1154.	1.2	16
16	COVID-19: dealing with a potential risk factor for chronic neurological disorders. Journal of Neurology, 2021, 268, 1171-1178.	1.8	50
17	Obstructive sleep apnea syndrome and Alzheimer's disease pathology: may continuous positive airway pressure treatment delay cognitive deterioration?. Sleep and Breathing, 2021, 25, 2135-2139.	0.9	14
18	Obstructive Sleep Apnea, Palatal Morphology, and Aortic Dilatation in Marfan Syndrome Growing Subjects: A Retrospective Study. International Journal of Environmental Research and Public Health, 2021, 18, 3045.	1.2	6

#	Article	IF	CITATIONS
19	Sleep disorders and late-onset epilepsy of unknown origin: Understanding new trajectories to brain amyloidopathy. Mechanisms of Ageing and Development, 2021, 194, 111434.	2.2	11
20	Perampanel effects on cognition and quantitative EEG in patients with epilepsy. Epilepsy and Behavior, 2021, 117, 107803.	0.9	2
21	Sleep problems affect quality of life in Parkinson's disease along disease progression. Sleep Medicine, 2021, 81, 307-311.	0.8	18
22	The Importance of Diagnosing and the Clinical Potential of Treating Obstructive Sleep Apnea to Delay Mild Cognitive Impairment and Alzheimer's Disease: A Special Focus on Cognitive Performance. Journal of Alzheimer's Disease Reports, 2021, 5, 515-533.	1.2	15
23	Assessment of self-reported and objective daytime sleepiness in adult-onset myotonic dystrophy type 1. Journal of Clinical Sleep Medicine, 2021, 17, 2383-2391.	1.4	5
24	Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations. Frontiers in Neurology, 2021, 12, 678373.	1.1	14
25	Perampanel effectiveness and tolerability in patients with epilepsy at long-term follow-up. Epilepsy and Behavior, 2021, 121, 108069.	0.9	18
26	Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurology, The, 2021, 20, 671-684.	4.9	116
27	The actigraphic documentation of circadian sleep-wake rhythm dysregulation in myotonic dystrophy type 1. Sleep Medicine, 2021, 88, 134-139.	0.8	5
28	Effects of anti-seizure medications on sleep architecture and daytime sleepiness in patients with epilepsy: A literature review. Sleep Medicine Reviews, 2021, 60, 101559.	3.8	44
29	Perampanel may represent an effective treatment for the prevention of migraine comorbid with epilepsy. Epilepsy and Behavior, 2021, 125, 108391.	0.9	5
30	More than sleep and wake disturbances: an actigraphic study showing the sleep-wake pattern dysregulation in epilepsy Seizure: the Journal of the British Epilepsy Association, 2021, 94, 95-99.	0.9	7
31	In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer's disease phases. Alzheimer's Research and Therapy, 2021, 13, 187.	3.0	29
32	Seasonality of restless legs syndrome: symptom variability in winter and summer times. Sleep Medicine, 2020, 66, 10-14.	0.8	4
33	Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer's disease course. Alzheimer's Research and Therapy, 2020, 12, 5.	3.0	39
34	Lateralization of cochlear dysfunction as a specific biomarker of Parkinson's disease. Brain Communications, 2020, 2, fcaa144.	1.5	6
35	Physical Activity Changes and Correlate Effects in Patients with Parkinson's Disease during <scp>COVID</scp> â€19 Lockdown. Movement Disorders Clinical Practice, 2020, 7, 797-802.	0.8	53
36	Laterality of Auditory Dysfunction in Parkinson's Disease. Movement Disorders, 2020, 35, 1283-1284.	2.2	4

#	Article	IF	CITATIONS
37	Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. Neurological Sciences, 2020, 41, 2671-2674.	0.9	6
38	Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a realâ€world, observational, retrospective study. Epileptic Disorders, 2020, 22, 309-316.	0.7	15
39	PAP use in mild cognitive impairment to delay progression to dementia. Journal of Clinical Sleep Medicine, 2020, 16, 1397-1397.	1.4	4
40	Autonomic symptoms, cardiovascular and sudomotor evaluation in de novo type 1 narcolepsy. Clinical Autonomic Research, 2020, 30, 557-562.	1.4	9
41	Autonomic functions in focal epilepsy: A comparison between lacosamide and carbamazepine monotherapy. Journal of the Neurological Sciences, 2020, 418, 117095.	0.3	5
42	Shedding Light on Nocturnal Movements in Parkinson's Disease: Evidence from Wearable Technologies. Sensors, 2020, 20, 5171.	2.1	18
43	Sleep-Wake Cycle in Alzheimer's Disease Is Associated with Tau Pathology and Orexin Dysregulation. Journal of Alzheimer's Disease, 2020, 74, 501-508.	1.2	47
44	Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy. Neurological Sciences, 2020, 41, 1373-1375.	0.9	59
45	Pitolisant for treating narcolepsy comorbid with Parkinson's disease. Sleep Medicine, 2020, 69, 86-87.	0.8	4
46	Compliance with levodopa-carbidopa intestinal gel in a selected population in central south Italy: Beyond sex, a possible gender effect. Parkinsonism and Related Disorders, 2020, 73, 57-59.	1.1	0
47	Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain, Behavior, and Immunity, 2020, 88, 11-16.	2.0	159
48	CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study. CNS and Neurological Disorders - Drug Targets, 2020, 19, 142-147.	0.8	4
49	Sleep and wake impairment in patients with SARS-CoV2 infection. Sleep Medicine, 2020, 73, 177-178.	0.8	0
50	Mechanisms of action underlying the efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: central role of disease severity. European Journal of Neuroscience, 2019, 49, 805-816.	1.2	20
51	Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first addâ€on therapy compared to levetiracetam and valproic acid. CNS Neuroscience and Therapeutics, 2019, 25, 632-637.	1.9	9
52	Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study. Neurological Sciences, 2019, 40, 1377-1382.	0.9	27
53	Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study. Epilepsy and Behavior, 2019, 94, 178-182.	0.9	14
54	Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and α-synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study. Parkinsonism and Related Disorders, 2019, 64, 97-105.	1.1	22

#	Article	IF	CITATIONS
55	Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study. Epilepsy and Behavior, 2019, 101, 106592.	0.9	21
56	Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. Neurobiology of Aging, 2019, 73, 61-67.	1.5	75
57	Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease. Journal of Neurology, 2019, 266, 636-641.	1.8	28
58	Postural and vestibular changes related to CPAP treatment in moderate-to-severe OSA patients: a 12-month longitudinal study. Sleep and Breathing, 2019, 23, 665-672.	0.9	13
59	New revolution in the assessment of cerebrospinal fluid orexinâ€A: Enzymeâ€linked immunosorbent assay!. Psychiatry and Clinical Neurosciences, 2019, 73, 194-195.	1.0	4
60	Obstructive sleep apnea may induce orexinergic system and cerebral β-amyloid metabolism dysregulation: is it a further proof for Alzheimer's disease risk?. Sleep Medicine, 2019, 56, 171-176.	0.8	53
61	CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD. Current Neurology and Neuroscience Reports, 2019, 19, 3.	2.0	13
62	Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis. British Journal of Clinical Pharmacology, 2019, 85, 240-244.	1.1	21
63	Does continuous positive airway pressure treatment affect autonomic nervous system in patients with severe obstructive sleep apnea?. Sleep Medicine, 2018, 42, 68-72.	0.8	9
64	Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study. Epilepsy and Behavior, 2018, 80, 173-176.	0.9	40
65	Is It Time to Consider Obstructive Sleep Apnea Syndrome a Risk Factor for Alzheimer's Disease?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 855-856.	2.5	9
66	Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients. Sleep Medicine, 2018, 41, 113-114.	0.8	16
67	Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine. Epilepsy & Behavior Case Reports, 2018, 10, 35-37.	1.5	16
68	Does fatigue in Parkinson's disease correlate with autonomic nervous system dysfunction?. Neurological Sciences, 2018, 39, 2169-2174.	0.9	7
69	Comparative Sleep Disturbances in Myotonic Dystrophy Types 1 and 2. Current Neurology and Neuroscience Reports, 2018, 18, 102.	2.0	19
70	Cerebrospinal Fluid Orexin Levels and Nocturnal Sleep Disruption in Alzheimer's Disease Patients Showing Neuropsychiatric Symptoms. Journal of Alzheimer's Disease, 2018, 66, 993-999.	1.2	22
71	Daytime autonomic activity in idiopathic rapid eye movement sleep behavior disorder: a preliminary study. Sleep Medicine, 2018, 52, 163-167.	0.8	19
72	Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study. Parkinsonism and Related Disorders, 2018, 57, 80-81.	1.1	25

#	Article	IF	CITATIONS
73	When Cognitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression. Frontiers in Aging Neuroscience, 2018, 10, 38.	1.7	25
74	Continuous Positive Airway Pressure Treatment May Improve Optic Nerve Function in Obstructive Sleep Apnea: An Electrophysiological Study. Journal of Clinical Sleep Medicine, 2018, 14, 953-958.	1.4	12
75	Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment. Neurochemistry International, 2017, 105, 58-63.	1.9	33
76	Physical activity contradictorily affects bone mineral density in obstructive sleep apnea patients at different ages. Sleep Medicine, 2017, 32, 273.	0.8	0
77	Effects of adjunctive perampanel on sleep quality, daytime somnolence and cognition in refractory focal epilepsy: further data Epilepsy and Behavior, 2017, 67, 137-138.	0.9	13
78	Subthalamic nucleus deep brain stimulation on motor-symptoms of Parkinson's disease: Focus on neurochemistry. Progress in Neurobiology, 2017, 151, 157-174.	2.8	30
79	Obstructive sleep apnoea as a risk factor for osteopenia and osteoporosis in the male population: further data and comments. European Respiratory Journal, 2017, 49, 1602471.	3.1	1
80	Obstructive Sleep Apnea is Associated With Early but Possibly Modifiable Alzheimer's Disease Biomarkers Changes. Sleep, 2017, 40, .	0.6	113
81	Intermittent Short Sleep May Contribute to Orexinergic Signaling Dysregulation in Alzheimer's Disease. Sleep, 2017, 40, .	0.6	1
82	Integrating postural and vestibular dimensions to depict impairment in moderateâ€ŧoâ€severe obstructive sleep apnea syndrome patients. Journal of Sleep Research, 2017, 26, 487-494.	1.7	43
83	Complement system dysregulation in patients affected by Idiopathic Generalized Epilepsy and the effect of antiepileptic treatment. Epilepsy Research, 2017, 137, 107-111.	0.8	17
84	Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease. Journal of Neurology, 2017, 264, 2215-2223.	1.8	39
85	Vitamin D status of male OSAS patients improved after long-term CPAP treatment mainly in obese subjects. Sleep Medicine, 2017, 29, 81-85.	0.8	30
86	Sleep apnoeas may represent a reversible risk factor for amyloid- $\hat{\mathbf{l}}^2$ pathology. Brain, 2017, 140, e75-e75.	3.7	23
87	Commentary: Sleep Changes without Medial Temporal Lobe or Brain Cortical Changes in Community-Dwelling Individuals with Subjective Cognitive Decline. Frontiers in Neurology, 2017, 8, 262.	1.1	2
88	Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients. CNS and Neurological Disorders - Drug Targets, 2017, 16, 339-345.	0.8	12
89	Orexin and Alzheimer's Disease. Current Topics in Behavioral Neurosciences, 2016, 33, 305-322.	0.8	45
90	Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2040-2049.	3.3	73

#	Article	IF	CITATIONS
91	Epilepsy, amyloid-β, and D1 dopamine receptors: a possible pathogenetic link?. Neurobiology of Aging, 2016, 48, 161-171.	1.5	71
92	Optic Nerve Dysfunction in Obstructive Sleep Apnea: An Electrophysiological Study. Sleep, 2016, 39, 19-23.	0.6	26
93	Obstructive sleep apnoea and bone health. European Respiratory Journal, 2016, 48, 1249-1250.	3.1	2
94	Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time. Sleep and Breathing, 2016, 20, 277-283.	0.9	19
95	Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer's disease. Neurobiology of Aging, 2016, 40, 120-126.	1.5	96
96	Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Medicine, 2016, 21, 140-144.	0.8	55
97	Effective treatment of nocturnal frontal lobe epilepsy with lacosamide: a report of two cases. Sleep Medicine, 2016, 23, 121-122.	0.8	10
98	Obstructive sleep apnoea as a risk factor for osteopenia and osteoporosis in the male population. European Respiratory Journal, 2016, 47, 987-990.	3.1	26
99	Development of Collateral Veins as a Favorable Prognostic Factor for Complete Recovery in Cerebral Venous Thrombosis Due to Tribulus Terrestris. International Journal of Stroke, 2015, 10, E66-E67.	2.9	6
100	Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder. Parkinsonism and Related Disorders, 2015, 21, 1476-1478.	1.1	4
101	Commentary: Clinical Correlates of Raphe Serotonergic Dysfunction in Early Parkinson's Disease. Frontiers in Neurology, 2015, 6, 261.	1.1	2
102	Estrogen Deficiency Hampers the Beneficial Effect of Continuous Positive Airway Pressure Therapy on Serum Vitamin D Concentrations in Postmenopausal Women Affected by Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine, 2015, 11, 1473-1474.	1.4	12
103	Continuous Positive Airway Pressure Treatment Increases Serum Vitamin D Levels in Male Patients with Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine, 2015, 11, 603-607.	1.4	47
104	MicroRNA expression is dysregulated in narcolepsy: a new evidence?. Sleep Medicine, 2015, 16, 1027-1028.	0.8	3
105	Chronic dopaminergic treatment in restless legs syndrome: does it affect the autonomic nervous system?. Sleep Medicine, 2015, 16, 1071-1076.	0.8	10
106	CSF lactate levels, Ï" proteins, cognitive decline: a dynamic relationship in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 655-659.	0.9	108
107	Symptomatic nonconvulsive status epilepticus erroneously suggestive of sporadic Creutzfeldt–Jakob disease. Journal of the Neurological Sciences, 2015, 348, 274-276.	0.3	9
108	Bilateral thalamic stroke due to nasal ephedrine and naphazoline use. Neurological Sciences, 2015, 36, 1285-1286.	0.9	4

#	Article	IF	CITATIONS
109	Nocturnal frontal lobe epilepsy with paroxysmal arousals due to CHRNA2 loss of function. Neurology, 2015, 84, 1520-1528.	1.5	32
110	Refractory restless legs syndrome remitting after dual kidney transplantation. Parkinsonism and Related Disorders, 2015, 21, 81-83.	1.1	2
111	<scp>CSF</scp> betaâ€amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis?. Journal of Sleep Research, 2014, 23, 420-424.	1.7	37
112	Effects of epilepsy treatment on sleep architecture and daytime sleepiness: An evidenceâ€based review of objective sleep metrics. Epilepsia, 2014, 55, 777-778.	2.6	3
113	Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and selfâ€reported questionnaires. European Journal of Neurology, 2014, 21, 929-934.	1.7	37
114	Lacosamide as add-on treatment of focal symptomatic epilepsy in a patient with alcoholic liver cirrhosis. Epilepsy & Behavior Case Reports, 2014, 2, 161-163.	1.5	2
115	Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease. JAMA Neurology, 2014, 71, 1498.	4.5	262
116	May CSF beta-amyloid and tau proteins levels be influenced by long treatment duration and stable medication in narcolepsy?. Sleep Medicine, 2014, 15, 1424.	0.8	7
117	Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia. Journal of Neurology, 2014, 261, 1832-1836.	1.8	25
118	Sleep disorders in spinal and bulbar muscular atrophy (Kennedy's disease): a controlled polysomnographic and self-reported questionnaires study. Journal of Neurology, 2014, 261, 889-893.	1.8	21
119	Fronto-central monomorphic theta activity as EEG pattern of ictal psychosis. Journal of the Neurological Sciences, 2014, 337, 240-242.	0.3	2
120	Multiple sleep latency test may be not sensitive in obstructive sleep apnea with comorbid narcolepsy revealed by low cerebrospinal fluid orexin levels. Sleep Medicine, 2014, 15, 1171.	0.8	2
121	Unexpected total recovery in a patient with post-anoxic complete alpha coma predicted by recording of cortical SEPs. Clinical Neurophysiology, 2013, 124, 2450-2453.	0.7	2
122	May a suspicious psychiatric disorder hide sporadic hemiplegic migraine? Genetic test as prompting factor for diagnosis. Neurological Sciences, 2013, 34, 1845-1846.	0.9	4
123	Sleep-Wake Cycle and Daytime Sleepiness in the Myotonic Dystrophies. Journal of Neurodegenerative Diseases, 2013, 2013, 1-13.	1.1	23